latest news

European Hematology Association Congress

Date : 28.05.2018

Curewize is proud to be presenting results at the 23rd EHA congress in Sweden, June 16 2018: 1.  ProALLBM clinical trial on AIEOP B-ALL cohort  and 2. miR-451 tumor suppresor study. 

Read More

Successful Completion of ProALL-BM Clini

Date : 03.04.2018

Curewize successfully completed the clinical trial of its lead product ProALLBM on a cohort of acute lymphoblastic leukemia (ALL) patients from a European National Registry Study. ProALLBM is being produced for deciding on ALL patients risk-based treatment group, varying from standard to i ...

Read More

Patent Allowance by Israel Patent Office

Date : 24.01.2017

Curewize Health Ltd., a diagnostic company focused on the development of proprietary diagnostics for the treatment of Acute Lymphoblastic Leukemia (ALL), announced that the Israeli Patent Authority has indicated on January 24, 2017 that it intends to grant a patent relating to Curewize’s ProAL ...

Read More

ProALL Blood Trial Presented at ASH 2016

Date : 07.12.2016

Curewize presented results of our retrospective clinical trial showing the correlation of ProALL microRNA in blood to microRNA in Bone Marrow at the 58th Annual Meeting and Exposition of the American Society of Hematology in San Diego December 2016. The Poster presented by Curewize's team "Mir ...

Read More

Patent Allowance by European Patent Offi

Date : 20.09.2016

Curewize Health Ltd., a diagnostic company focused on the development of proprietary diagnostics for the treatment of Acute Lymphoblastic Lukemia (ALL), announced that the European Patent Office (“EPO”) has indicated on September 15, 2016 that it intends to grant a patent relating to Cur ...

Read More

microRNA Predict Acute Lymphoblastic Leu

Date : 21.12.2015

Curewize is proud to announce the publication of our researchers work on the ProALL technology. The pubication miR expression profiling at diagnosis predicts relapse in pediatric precursor B-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer. Avigad et al., 2016;55:328-339 shows t ...

Read More